drugset / Trial / NCT00503204

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

NCT00503204

Phase 1 Completed 20 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

Timeline

Start
2007-09
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral
Background Lomustine Small molecule Oral